Review

Role of Aggressive LDL Reduction in Patients With Coronary Heart Disease

Authors: Cassandra D. Benge, PharmD, Brandon Markley, PharmD, Michael Shawn McFarland, PharmD

Abstract

Abstract: The aim of the present study was to integrate research evidence with the care of the patient with coronary heart disease (CHD) and place into perspective the importance of intensive statin therapy. We reviewed five major trials and select related post hoc analyses that examined the beneficial effects from intensive low-density lipoprotein (LDL) reduction on combined morbidity and mortality end points in patients with stabilized CHD and those with recent acute coronary syndrome.


Accumulating evidence since the publication of the pivotal Heart Protection Study and Adult Treatment Panel III supports a more intensive LDL reduction than that recommended in the 2004 Adult Treatment Panel III update. An LDL reduction of 49% from baseline in statin-naïve patients with stable CHD or a 41% to 44% reduction in LDL from postadmission values in patients with acute coronary syndrome improves composite morbidity and mortality end points.


Current evidence suggests that a more intensive LDL reduction of approximately 45% to 50% from a patient’s baseline in acute and stable CHD is warranted. The decrease in recurrent events associated with the use of statin regimens that can achieve this degree of reduction in LDL may offer a financial incentive for managed care healthcare systems; however, statin therapy should be selected upon careful consideration of both dose and agent.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
 
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7–22.
 
3. Sheperd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. PROspective study of Pravastatin in the Elderly at Risk. Lancet 2002; 360: 1623–1630.
 
4. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997.
 
5. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149–1158.
 
6. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy—Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N Engl J Med 2004; 350: 1495–1504.
 
7. Grundy SM, Cleeman JI, Bairey Merz NC, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227–239.
 
8. Lemons JA, Blazing MA, Wivott ST, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z Trial. JAMA 2004; 292: 1307–1316.
 
9. Larosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. Treating to New Targets (TNT) Investigators. N Engl J Med 2005; 352: 1425–1435.
 
10. Pedersen TR, Faegeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. The Incremental Decrease in Endpoints Through Aggressive Lipid Lowering (IDEAL). JAMA 2005; 294: 2437–2445.
 
11. SEARCH Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12064 survivors of myocardial infarction: a double-blind randomized trial. Lancet 2010; 376: 1658–1660.
 
12. Lipitor [product information]. New York, NY: Parke-Davis, Division of Pfizer Pharmaceuticals; 2009.
 
13. Crestor [product information]. Wilmington, DE: Astra-Zeneca Pharmaceuticals; 2011.
 
14. Livalo [product information]. Montgomery, AL: Kowa Pharmaceuticals America, Inc, and Lilly USA, LLC; 2011.
 
15. Zocor [product information]. Whitehouse Station, NJ: Merck & Co., Inc; 2011.
 
16. Mevacor [product Information]. Whitehouse Station, NJ: Merck & Co., Inc; 2010.
 
17. Pravachol [product information]. Bristol-Myers Squibb Company. May 2011, Princeton, New Jersey 08543.
 
18. Lescol [product information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011.
 
19. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7–22.
 
20. Kausik KR, Cannon CP, McCabe CH, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndrome: results from the PROVE IT-TIMI 22 Trial. J Am Coll Cardiol 2005; 46: 1405–1410.
 
21. Wivott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy. J Am Coll Cardiol 2005; 46: 1411–1416.
 
22. LaRosa JC, Deedwania PC, Shepherd J, et al. Comparison of 80 mg versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] Trial). Am J Cardiol 2010; 105: 283–287.
 
23. Tikkanen MJ, Szarek M, Fayyad R, et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy. Insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) Trial. J Am Coll Cardiol 2009; 54: 2353–2357.
 
24. Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. JAMA 2011; 305: 2556–2564.
 
25. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–599.
 
26. Heart Protection Study Collaborative Group. Effects of cholesterollowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757–767.
 
27. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. The German Diabetes and Dialysis Study (4D). N Engl J Med 2005; 353: 238–248.
 
28. Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670–1681.
 
29. Egan A, Colman E. Weighing the benefits of high dose simvastatin against the risk of myopathy. N Engl J Med 2001; 365: 285–287.
 
30. Reiner Z, Catapano A, de Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias. The Task Force on the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–1818.